

CURRICULUM VITAE

Name: JOSE ALFREDO GOMEZ PUERTA
Date of birth 9 of July 1975
Office Address: Calle Villarroel 170, Escalera 11-2 planta, Rheumatology Department, Hospital Clinic, 08026, Barcelona, Spain



Place of Birth: Medellín, Colombia
Nationality: Colombian and Spanish
Current position: Head of Department, Department of Rheumatology, Hospital Clinic, Barcelona, Spain
Associate Professor, Universitat de Barcelona

- Education

1993-1998	MD	Degree in Medicine and Surgery	Instituto de Ciencias de la Salud, CES; Medellín, Colombia
1999-2002	Internal Medicine	Official Residency Program to become a Specialist in Internal Medicine,	Universidad Pontificia Bolivariana, Medellín-Colombia
2004-2008	Rheumatology	Official Residency Program to become a Specialist in Rheumatology, Hospital Clínic, Barcelona	Hospital Clínic, Barcelona , Spain
2007	PhD <i>summa cum laude</i>	Doctoral Degree in Biopathology, Universidad de Barcelona	Universitat de Barcelona, Spain
2011-2012	Master	Master in Autoimmune Diseases	Universitat de Barcelona, Spain

2012	Program in Clinical Effectiveness		Harvard School of Public Health, Boston, MA, USA
2012-2014	MPH	Master in Public Health	Harvard School of Public Health, Boston, MA, USA

- Appointments at Hospitals

01/97-04/97	Medical student	Rheumatology Unit	Guy's Hospital, London, UK
05/97-06/97	Medical student	Lupus Unit	St Thomas's Hospital, London, UK
04/01-07/01	Research fellow	Lupus Unit	St Thomas's Hospital, London, UK
11/11- 06/14	Post-Doctoral Research fellow	Division of Rheumatology	Brigham & Women's Hospital, Boston, USA Harvard Medical School

- Visits at excellence centers

2009	Leiden Medical Center, Arthritis Unit, Leiden, Netherland
2010	Kariolinska Institute, Rheumatology Department, Sweden
2011	Massachusetts General Hospital and Brigham & Women Hospital at Harvard Medical School, Boston, USA

- Professional Societies

2005-	Catalan Society of Rheumatology	Member
2006-	Spanish Society of Rheumatology	Member
2009-	Colombian Society of Rheumatology	Member
2012-	American College of Rheumatology	Research member
2017	Argentinian Society of Rheumatology	Honorary member
2019	Chilean Society of Rheumatology	Honorary member

- Honors and Prizes

2003	Abbott Abstract Award,	EULAR, Annual European Congress of Rheumatology.	
2008	Emili Letang	Hospital Clinic, Barcelona	Best Fellow
2011	Grant for studies abroad	Catalan Society of Rheumatology	
2011	Grant for studies abroad	Spanish Society of Rheumatology	
2012	Bursary grant	EULAR	
2012	Research grant	Fundación Alfonso Martín Escudero, Madrid, Spain	
2013	Excellence in Rheumatology, Fernando Chalem	Colombian Society of Rheumatology	
2014	Research Grant	COLCIENCIAS	
2015	Abstract Award	11 th International Congress on SLE, Vienna, Austria	Second Place, Basic Science

-Scientific production

Published articles 169 (indexed articles)

H index 41

Brief summary

I am specialist in Internal Medicine from the Universidad Pontificia Bolivariana, Medellín, Colombia, and a rheumatologist at Hospital Clínic of the University of Barcelona, Spain. He was awarded a PhD in Biopathology by the University of Barcelona in 2008.

I received further training in the Rheumatology Unit at Guy's Hospital, London, UK, and in the Lupus Unit at St. Thomas' Hospital, London, UK, in 1997 and 2001, respectively.

I also completed a Master's degree in Autoimmune Diseases at the University of Barcelona and was appointed as a Postdoctoral Research Fellow at Brigham and Women's Hospital, Harvard Medical School, Boston, USA, from 2011 to 2014.

In 2014, I obtained a Master of Public Health degree from the Harvard School of Public Health, Boston, USA.

My work has focused on the study of autoimmune and immune-mediated diseases. He has published approximately 170 original articles, brief reports, or

reviews in peer-reviewed journals, as well as over 200 communications at national and international meetings.

I am co-investigator of the GLADEL 2.0 study group, former member of the Executive Committee of SLEuro, and a member of the ACR/EULAR task force on immune-mediated adverse effects of checkpoint inhibitors and active member of other SLE related working groups including OMERACT, SLAKE and ERN ReCONNECT – SLICC – SLEuro consensus on the therapeutic management of rare SLE manifestations.

I am member of the Catalan, Spanish, and Colombian Societies of Rheumatology, an honorary member of the Argentinean and Chilean Societies of Rheumatology, and a member of the American College of Rheumatology.

Currently, I am Head of the Department of Rheumatology at Hospital Clínic, Barcelona, and Associate Professor of Rheumatology at the University of Barcelona, Spain.

Articles published recently in SLE

1. International SLAKE development group. International development and validation of a multilingual bank of items for the self-assessment of essential knowledge by systemic lupus erythematosus patients: the SLE Knowledge Assessment score (SLAKE).

Satrin A, Piga M, Gatto M, Fuentes-Silva Y, **Gómez-Puerta JA**, Padjen I, Pons-Estel G et al. Rheumatology (Oxford). 2025 Dec 12:keaf649

2. Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis

Izcovich A, Tortosa F, Bengolea A, Pissinis MM, Ragusa M, Fielli M, Agnoletti C, Quintana R, Malvar A, Scolnik M, Bonfá E, Borba EF, Monticeli OA, Dos Reis-Neto ET, Massardo L, **Gómez-Puerta JA**, Toro-Gutiérrez CE, Esquivel-Valerio JA, Loyo HF, Mejia-Vilet JM, Alarcón GS, Ugarte-Gil MF, Pons-Estel BA, Pons-Estel G; Grupo Latino Americano de Estudio del Lupus (GLADEL).. Kidney Int Rep. 2025 Jul 3;10(9):2977-2990. doi: 10.1016/j.ekir.2025.06.047.

3. Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions. Barbhaiya M, Zuily S, Jannat-Khah D, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, de Jesús GR, Devreese KMJ, García D, **Gómez Puerta JA**, Guillemín F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou M, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader KH, Erkan D; New APS Classification Criteria Collaborators. Arthritis Care Res (Hoboken). 2025 Jul 7. doi: 10.1002/acr.25599. Online ahead of print.

4. ERN ReCONNECT-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S,

Dall'Era M, Adelowo O, Bae SC, Beretta L, Bonfa E, Cervera R, Chasset F, Clarke AE, Costedoat-Chalumeau N, Doria A, Espinosa G, Fanouriakis A, Fredi M, Gatto M, Gladman DD, **Gomez-Puerta JA**, Inanc M, Ines LS, Isenberg D, Izuka S, Khmelinskii N, Legge A, Macieira C, Monticelo OA, Morand EF, Muñoz-Louis R, Padjen I, Petri M, Piga M, Pons-Estel BA, Ramirez GA, Ramsey-Goldman R, Richez C, Sciascia S, Toro-Gutierrez CE, Van Vollenhoven RF, Vital EM, Gerosa M, Touma Z, Mosca M, Tani C; European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal, Diseases; Systemic Lupus Erythematosus International Collaborating Clinics group; European Lupus Society rare systemic lupus erythematosus taskforce member panel. *Lancet Rheumatol*. 2025 Jul;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3. Epub 2025 May 23.

5. Dual B-cell targeting in systemic lupus erythematosus: The role of combined and sequential therapy with rituximab and belimumab.

Frade-Sosa B, Sarmiento-Monroy JC, Bruce IN, Arnaud L, **Gómez-Puerta JA**. *Autoimmun Rev*. 2025 Jul 31;24(8):103837. doi: 10.1016/j.autrev.2025.103837. Epub 2025 May 23.

6. Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set. Nielsen W, Kharouf F, Grajales CM, Thayaparan A, Anderson M, Strand V, Simon L, Bonilla D, Morand E, Thumboo J, Aringer M, Mosca M, Bruce I, Papadopoulos EJ, Torralba KD, Whittall-Garcia LP, Rosen CF, Parodis I, Kim A, Desai M, Enman Y, Shea B, Wallace DJ, Chaichian Y, Navarra S, Aranow C, Mackay M, Trotter K, Tayer-Shifman OE, Duarte-García A, Shan Tam L, Ugarte-Gil MF, Pons-Estel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Aggarwal A, Papachristos D, Mok CC, Fujio K, Ramsey-Goldman R, Legge A, Arnaud L, Bultink IEM, Finzel S, Voll RE, Ruiz-Irastorza G, Inês LS, Appenzeller S, Dobrowolski C, Clarke AE, Kamen DL, Barraclough M, Tani C, **Gómez-Puerta JA**, Werth VP, Katz P, Askanase AD, Bingham K, Gladman DD, Johnson S, Drucker A, Nowrouzi-Kia B, Touma Z; OMERACT SLE Working Group. *Semin Arthritis Rheum*. 2025 Jun;72:152684. doi: 10.1016/j.semarthrit.2025.152684. Epub 2025 Feb 27.

7. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task force.

Piga M, Parodis I, Touma Z, Legge A, Ugarte-Gil MF, Hmamouchi I, **Gómez Puerta JA**, Devilliers H, Zen M, Cho J, Ziade N, Mucke J, Toro-Gutierrez CE, Izuka S, Korsten P, Kane BSY, Golder V, Chong BF, Pons-Estel G, Chasset F, Arnaud L.

Autoimmun Rev. 2025 Apr 30;24(5):103773. doi: 10.1016/j.autrev.2025.103773. Epub 2025 Feb 15.

8. Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients.

Pons-Estel GJ, Quintana R, Ugarte-Gil MF, Harvey GB, Wojdyla D, Serrano-Morales R, **Gómez Puerta JA**, García MA, Catoggio LJ, Saurit V, Drenkard C, Da Silva NA, Cavalcanti F, Borba E, Sato E, Neira O, Massardo L, Vásquez G, Gonzalez LA, Guibert-Toledano M, Silveira LH, García De La Torre I, Sauza Del Pozo MJ, Chacón R, Cardiel MH, Orillion A, Sbarigia U, Alemao E, Zazzetti F, Alarcón GS, Pons-Estel BA.

Lupus. 2024 Nov;33(13):1492-1501. doi: 10.1177/09612033241283551. Epub 2024 Sep 11.

9. Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.

Barbhaiya M, Zuily S, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, Crowther M, Ramires de Jesus G, Devreese KMJ, Frances C, Garcia D, **Gómez-Puerta JA**, Guillemain F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou MG, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators.

Arthritis Care Res (Hoboken). 2024 Dec;76(12):1617-1625. doi: 10.1002/acr.25415. Epub 2024 Sep 30.

10. OMERACT systemic lupus erythematosus domain survey.

Nielsen W, Strand V, Simon L, Pinsker E, Bonilla D, Morand E, Thumboo J, Aringer M, Mosca M, Bruce I, Parodis I, Kim A, Desai M, Enman Y, Shea B, Wallace DJ, Chaichian Y, Navarra S, Aranow C, Mackay M, Trotter K, Tayer-Shifman OE, Duarte-García A, Shan Tam L, Ugarte-Gil MF, Pons-Estel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Aggarwal A, Mok CC, Fujio K, Ramsey-Goldman R, Gladman DD, Arnaud L, Bultink IEM, Ruiz-Irastorza G, Inês LS, Appenzeller S, Dobrowolski C, Clarke AE, Kamen DL, Barraclough M, Tani C, **Gómez-Puerta JA**, Werth VP, Katz P, Nowrouzi-Kia B, Johnson SR, Drucker AM, Touma Z; OMERACT SLE Working Group.

Semin Arthritis Rheum. 2024 Oct;68:152520. doi: 10.1016/j.semarthrit.2024.152520..

11. Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.

Farisogullari B, Lawson-Tovey S, Hyrich KL, Gossec L, Carmona L, Strangfeld A, Mateus EF, Schäfer M, Rodrigues A, Hachulla E, **Gomez-Puerta JA**, Mosca M, Durez P, Trefond L, Goulenok T, Cornalba M, Stenova E, Bulina I, Strakova E, Zepa J, Roux N, Brocq O, Veillard E, Raffener B, Burmester GR, Mariette X, Machado PM; EULAR COVAX Registry.

Ann Rheum Dis. 2024 Oct 21;83(11):1584-1595. doi: 10.1136/ard-2024-225869.

14. Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?

Rúa-Figueroa I, Altabás-González I, Mouriño C, Roberts K, Hernández-Martín A, Casafont-Solé I, Font-Urgelles J, Román-Ivorra JA, de la Rubia Navarro M, Galindo-Izquierdo M, Salman-Monte TC, Narváez J, Vidal-Montal P, García-Villanueva MJ, Garrote-Corral S, Blázquez-Canamero MA, Fernandez-Cid CM, Piqueras-García M, Martínez-Barrio J, Sánchez-Lucas M, Cortés-Hernández J, Penzo E, Calvo-Alén J, de Dios JR, Álvarez-Rodríguez B, Vasques-Rocha M, Tomero E, Menor-Almagro R, Gandía M, **Gómez-Puerta JA**, Frade-Sosa B, Ramos-Giráldez C, Trapero-Pérez C, Díez E, Moriano C, Muñoz-Jiménez A, Pego-Reigosa JM. *Rheumatology (Oxford)*. 2025;64(3):1220-1224. doi: 10.1093/rheumatology/keae270.

15. Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.

Altabás-González I, Pego-Reigosa JM, Mouriño C, Jiménez N, Hernández-Martín A, Casafont-Solé I, Font Urguelles J, Román-Ivorra JA, de la Rubia Navarro M, Galindo-Izquierdo M, Salman-Monte TC, Narváez J, Vidal-Montal P, García-Villanueva MJ, Garrote-Corral S, Blázquez-Cañamero MÁ, Marras C, Piqueras-García M, Martínez-Barrio J, Sánchez-Lucas M, Cortés-Hernández J, Penzo E, Calvo-Alén J, de Dios JR, Álvarez Rodríguez B, Vasques-Rocha M, Tomero E, Menor-Almagro R, Gandía M, **Gómez-Puerta JA**, Frade-Sosa B, Ramos-Giráldez C, Trapero-Pérez C, Díez E, Moriano C, Muñoz-Jiménez A, Rúa-Figueroa IJ. *Rheumatology (Oxford)*. 2025 Jan 1;64(1):276-282

16. Real-world data on anifrolumab, the new kid on the block in lupus.

Gómez-Puerta JA. *Rheumatology (Oxford)*. 2024 Sep 1;63(9):2325-2327.

17. Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice

Frade-Sosa B, Salman-Monte TC, Narváez J, Peralta I, Sandoval S, Magallares B, Heredia S, Sapena N, Riveros-Frutos A, Olivé A, Corominas H, Cortés-Hernández J, **Gómez-Puerta JA**. *Lupus*. 2024 Apr;33(5):481-489

Barcelona, 23rd of January

Dear Members of the SLEuro Executive Committee,

I am writing to express my strong interest in rejoining the Executive Committee of SLEuro.

During the two years I had the privilege of serving on the Committee, I was able to experience firsthand the essential educational and dissemination role that SLEuro plays, both in advancing medical education in systemic lupus erythematosus and in promoting patient education and engagement across Europe. Being part of the Committee allowed me to better understand the impact of SLEuro's activities and its collaborative spirit, which I greatly value.

In addition, I had the opportunity to organize the 5th *SLEuro Advanced Workshop on SLE* in October 2024 in Barcelona. This experience was particularly rewarding, as the meeting achieved a high academic standard and received very positive feedback from participants, reinforcing my commitment to SLEuro's mission and objectives.

For all these reasons, I would be honored to continue contributing to SLEuro and to once again be part of the SLEuro Executive Committee family. I remain highly motivated to actively support its educational initiatives, scientific activities, and future projects.

Thank you very much for your consideration.

Kind regards,



Jose A. Gómez Puerta, MD, PhD, MPH

Head of Rheumatology Department, Hospital Clínic de Barcelona

Associate Professor, Universitat de Barcelona